Arnold Oronsky

Bio

Arnie has been a full-time member of InterWest's healthcare team since 1994. He is a board member of Centrexion Therapeutics, Dynavax Technologies (DVAX), EpicentRx, KalVista Pharmaceuticals (KALV), PMV Pharma, Prothex Pharmaceuticals, and Sera Prognostics. As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Arnie brings a deep understanding of medical research to finding and investing in successful healthcare companies. Prior to joining InterWest, Arnie was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs. Arnie received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals. Representiative Prior Investments: AkaRx (Acquired by Eisai Pharamaceuticals in 2009), Amplimmune (Acquired by Astrazeneca in 2013), Aspreva Pharmaceuticals (IPO 2006, ASPV, acquired by Galenica 2008), Corixa (IPO 1997, CRXA), Coulter Pharmaceuticals (Acquired by Corixa in 2000), Cubist (IPO 1996, CBST), MacroGenics (IPO 2013, MGNX), Myogen (IPO 2003), Potenza Therapeutics (Acquired by Astellas in 2018), Salmedix (Acquired by Cephalon in 2005), Signal Pharmaceuticals (Acquired by Celgene in 2000), Tesaro (IPO in 2012 TSRO, acquired by GSK in 2019).